New Call for Abstracts and Registration [International Conference on AIDS (8th: 1992: Amsterdam, Netherlands)]

;- ~-~---~~---~~~~~--- --~~~ -~~-----------C--I-~~-~--~~~~ -----~-~~-~~^^^x--~~-~ ~-~ ~~1;- ----~-~~~--~-~~j-i;~-;~;-- ~--;- ~--~~--i--~-~----- - --------------~-- --~~--~~~ ---- -~-------~-~~----- -~;~~-~~..--~~~-_. Il~.,l;.,~~..-...~.-_;~-;.,~.~~.. ~i~..r..:,~~-~i~i

Categories for Abstract
Submission
thr fc!iLowsin1 lKs, "I.11141rie2 tIorAbrat
""OH" 1 k-LNTM'HCwhik.h areg01r hest corr-c
Track A: Basic Science
HI Id I I1en0'!ruH (M
M 111n i /nd to,11n
it I'' HI
A1 1 A1111-111 1r I u
A 1 1 litmn 1111 11212 ýil
'1. ( 8n itinrs ne
A 13. Onco ILI T110s]: 1) ll IIIC
Tr1 AiackB Cmncls SineadCr
A I 4. V \Iu-II cC11 111i bmnoral immunI
A 1' Virus-sp1 ci4 celhdar i N
A 8 C - I II Immuno Ia"I hlole1".s a timmuIt
8A 8.lCytoki'el InI ILTu p.inkaion H'. atnenss
A1S. Virus variabilt H
A1 9. OIherII rt rovirses
)Is
A2 0. 1STIHDs p:ti11ctors for II1V i t o l.A--) Bac:tuvIafl STD ageurnt xad patho"('1C
A 2 Vir ( )T'D 11 m 1 d. -1, 111 k h110 a hn11k
81. 1 2 7 l0 ccfu1 r car1H 1I.1H21G.1114il hc'p 1n 1 8 TE
Track B: Clinical Science and Care
81 4.'lmirlro Li/tos
8 1. \',Icimic st
114. I)1men.. l irIW /IH HI 11V./ d oth1r'
P)(,. l eai' 1 4'I.nd l Sth r p4t1 l 1 1 (
LT In~fIL~lunCe Of I V i cio nml nfsain
311d nilural i 1stol-,(Ito r hcr S*T~s
B,10. Lymiphotm, mid othcr HIV-rebuLled neoplasms
)1 1 ). CerVital ad other IV-relmcd neopidsm"
B 12. Hepatocelu1a111 cIrCIiC 111.11 4Ild ej.1IISP
TihcHraPIfs
1 3. Antiretrovrirl
B 14. hImm i-ne-baowd th,.rapiecs/,.yNtokinecw
Bl 15 Vaýcclies

82 annes.,
Bio. Usneco ou ncludin:
use cs., n as
832. Other

8.
8 44.
111.
8i 4
11C.
81~.
8 46*
840I.

1'': 1 i
\1c. r1 n.1h,
1].1g
1111tio '
Id m'11:5 nu ma
1 1,,mco 1, i....

I1' 'X11

12. H elthl aw: legislation and litigation
I AdvocI ay,' - and1 sclft 11d cac.
Dý' Ethics: CliniCALbromwdicO, epidemiolg
rcstivrch. ind social reptnisibl~ity
DO. 'hICrole(A 1 'rgioi ind1 co. nscience
D7. -11H111CO1f1115 AMMInT1aand non-pywern
mntO alorqani/at
08. Distribunivc juvion and whosra titru c rhuddhig
D9. CCSWN IIdAiknah
HMalth Krov nv i Aaw luiceS jar HIM Aii0
alh dwothOIL~
0D IdU.v: wturona
1) 11. \ od1 s of ir and d1 12r1:
M 2. Traditoal h111
with IM,
D14. Orgaiditaw Nii pricnA n&
DI1 Acccss, mhs, finlanc nJrh g Ivc 11(
D16. 16,111 lth k r wtroinminkyon
D17. Waind cr iAN<

Track C: Epidemioloc
1., 1)7 'I:

g

11.
C 4.
( 8.
CR 8
CI 1,
C1. In
14,
1)2.
I 14.. 14.
C
Cl.
C 19.
C 21.

I 1,1 10cr 151M% O
Ni,).,.!! (I n l I
1 ':)Ils''
1)121,12 uO
'.1 1,.k
1115d eh

\I 511,12. 1
m litH1 \m ri, n
I 1 n c II 11.11..
12'!aad cana

D24,
1)1)5.
H21.
01)2.
01)2
1)24.
112

NOW iaand minioration dCIsninalkh,
Fducmion ard nd health prolom o
Scxud beManbDrug1 111 1
hilooid don'lil
Vert cl i 1 11 1t 1 1
N-ation1 All)''11 SD1111)1rolstrat1gies:
d~c',g 11 COOrd II, (m Oi. ',I cnic I I vtion., id
C V: tIa u t ion-,

OtWh ( mn

5k II'alla n t/m n

11.1 OrI/

149C v Ch wte
D2A. 1So1211.1114r.12111d hImpact m:
1114V a115.1T
DT Y Tsting and socreninig
1 c'8, ' 1rtiing1 1'potifictioIIt c public i' alth epartmen
D2L),.Internati1nal m 11111 1d programs
S13. Partnc r n 1 rtification/conta 'ct trmicinc
1)3 1. Piac conflidcntiahty amid powe,-r/du..ty tt
inform and';I~ght to know
D31. Trans,:fusion~transrilanitation o(A lodimniO ia
D33. C m u iyempoweVVrmn~oIt` 11d Im(obilization,
D34. Research and developmenciro( drugs and
vickines: msuen ()f control and design; cxpoedit-od
a1ccess; and dis~rnbutive Justice
I,'31 hnding resources: donors, governmental
suppwrt-j Illuvoluntary organizations
D,- )6. Needile policics.-nd drug law enforcemnen

C 2. Adoiecen":C!,
'24. 1Blood and blood pr1du11t2
C2) Drug user,
1 /6. D 1t.n1nin nts of 5i.1e )1/Ill.111
A I dlgc susad plcto
C-2 Application aiid performl-mx (J IHVIVSTD 4
diagnostic as,,ays in epd moo yStudies
C128. SurVeillancc methods 1for 1111V and STI)s
C2. Modeling, for. tn 111ai-aayssad
imipact Asscissnlent
3). Mlthodology of vaccin 1trials
(31. N LcthoIologs (1 1Ofint 1r1ntio.lllcl eCv u1111.l
C')2. 1Mthodolog1 of( 1l1ic trial'
13..M81 rc m t anlk'.111d d 1scrisI'll I 1n of S,11al h vir
`4. Mod1lin) of HIV mcdits HIS tvra1.tlon with the
'Phi A1 5211 1111111
4". STD prevention and rI11V transn1111
' 16. 1VA1luAti. 'of Interventi'o11 21 1 11 to prevent S al
transmission
FV7. Evu'ation ot 1itervetiMOHIS 10prevcnt HIV
trn msinthrOughinicTj0t111 ing drug use
C13 8. 1Evalutwton of o)ther, int~erventions to Prevent
IHIV'transmission
Track D: The Social Impact and Response
[H111.11 R1i/111. /t/11. and1, 1.111

-37.
1)319.
D41
D42.
1)43.
D44.
D4.
141.
14-.
1)48.
D149.

Pop( t111;11
Prlisoners and other Institutionalized populathill
11mgI T15C215
Young people)]
Lesblans 'Ind gays
Drug, userIs
Commrercial sex workers and14 ustonc'rs
I omeIless per1sons and street 1hIldren
AIDS orphans
Person" with hemlophilia
1iSCxulS.and transsexu'1Als
( 'ul'turL-T r1.iacial, soclial, and ethnic groulps
n1111111igrants, travelers, and refugees
P Iople living with IIVMAIMS

812
1121.
1122.
1124.
1124.
828.
826.

Clinical Rcstwlrch on.VST),
Pclhvic inflammiatory disceast
C"ervicail neoplasil
Pregnancy and ST~s
Genital ulcer diselse'.
Other
Organ Systems'
NervouIs s%-stem( ne ro11,'yc1tr
Psychology)
Pulmonary
pOr,' (I I

Supporntive Caire and Seruices
1)S0. Stress and coping a11 ong health care workers,
care givers, and families
1)8. Assessment and evaluation1
D1)2. In1vidual coun1s12ling.1nd p1sychotherapy
I ý3. Peer supljport
1) 4. Famrilly support
0 Counlsell ift
F) 6. Living w1rh1Y.IV D
D1) Role 1nd contri butitoll of volut1t111r12

82. Gastroi ntestil l1
828. Skinl

111 ~1 _._,_~__ ~1 1 1111~1 11 1~ 1111 1 I - 11 1~111 1 I - I